2016
Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso
Sondo P, Derra K, Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, Valéa I, Sorgho H, Owusu-Dabo E, Ouédraogo J, Guiguemdé T, Tinto H. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLOS ONE 2016, 11: e0151565. PMID: 27031231, PMCID: PMC4816516, DOI: 10.1371/journal.pone.0151565.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllelesAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsBurkina FasoChildDrug CombinationsEthanolaminesFemaleFluorenesGene FrequencyGenotypeHost-Parasite InteractionsHumansMalaria, FalciparumMaleMembrane Transport ProteinsMiddle AgedMultidrug Resistance-Associated ProteinsMultivariate AnalysisParasitemiaPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsTreatment OutcomeConceptsPfmdr1 allelesTreatment failureArtemether-lumefantrine therapyPfcrt K76TSingle nucleotide polymorphismsRestriction fragment length polymorphism methodFragment length polymorphism methodPotential beneficial effectsLength polymorphism methodArtesunate-AmodiaquineRecurrent parasitaemiaTreatment regimenACT resistanceCombination therapyK76TPfmdr1 geneClinical trialsTreatment outcomesMultivariate analysisDay 0PfcrtMalaria controlBlood spotsBeneficial effectsPolymorphism method
2006
In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs.
Tinto H, Sanou B, Erhart A, D'Alessandro U, Ouédraogo J, Guiguemdé T. In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs. Bulletin De La Société De Pathologie Exotique 2006, 99: 161-5. PMID: 16983817.Peer-Reviewed Original ResearchConceptsCQ treatment failureTreatment failureRisk factorsMultivariate analysisVivo field testTotal treatment failureYears of ageTime of recruitmentSignificant increaseSulfadoxine-pyrimethamineCQ groupUnivariate analysisHealth centersAge of childrenLate failureLow parasitaemiaBetter efficacyDay 14Therapeutic efficacyDay 0SP groupVivo sensitivityParasitaemiaChloroquineDrugs
2002
Chloroquine and sulphadoxine‐pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo‐Dioulasso, Burkina Faso during a 3‐year period 1998–2000
Tinto H, Zoungrana E, Coulibaly S, Ouedraogo J, Traoré M, Guiguemde T, Van Marck E, D'Alessandro U. Chloroquine and sulphadoxine‐pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo‐Dioulasso, Burkina Faso during a 3‐year period 1998–2000. Tropical Medicine And International Health 2002, 7: 925-930. PMID: 12390597, DOI: 10.1046/j.1365-3156.2002.00952.x.Peer-Reviewed Original ResearchConceptsPrevalence of anemiaClinical failureParasitological resistancePacked cell volumeUncomplicated malariaDay 14Day 0Uncomplicated malaria treatmentHaematological recoveryMalaria treatmentCQ resistanceHealth centersRegular surveillanceAntimalarial drugsChloroquineBurkina FasoPrevalenceBobo-DioulassoChildrenAnemiaEvidence of increasesMalariaTreatmentFailureCell volume
1992
Variation of the parasite density of Plasmodium falciparum in asymptomatic carriers: consequences for malaria chemoresistance studies.
Guiguemde T, Toe A, Sadeler B, Gbary A, Ouedraogo J, Louboutin-Croc J. Variation of the parasite density of Plasmodium falciparum in asymptomatic carriers: consequences for malaria chemoresistance studies. Medecine Tropicale 1992, 52: 313-5. PMID: 1435194.Peer-Reviewed Original ResearchConceptsDay 4Parasite densityDay 0Plasmodium falciparumAsymptomatic peopleAsymptomatic carriersInclusion criteriaMalaria prevalenceStudy 16Drug absorptionPrimary school childrenParasitaemiaBobo-DioulassoNycthemeral variationsFurther studiesSignificant differencesChildrenSchool childrenVivo testsFalciparumNegativationChemosensitivityGreater numberPrevalenceChemoresistance
1990
Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso).
Guiguemdé T, Sturchler D, Ouédraogo J, Drabo M, Etlinger H, Douchet C, Gbary A, Haller L, Kambou S, Fernex M. Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso). Bulletin De La Société De Pathologie Exotique 1990, 83: 217-27. PMID: 2119897.Peer-Reviewed Original ResearchConceptsDoses of TTAntibody titresCircumsporozoite proteinAverage antibody titresPeak IgG responseMonths of ageClinical malariaIgG responsesSystemic reactionsProtective efficacyVaccine trialsImmunological statusImmunisation vaccinesTetanus toxoidProtective effectGroup IIMalaria transmissionDay 0VaccineGroup IGroup IIIPlasmodium falciparumDay 75MalariaDay 150